Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer

Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer.

Om avsnittet

Fler avsnitt

Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Prostate Cancer — The Optimal Use of Hormonal Therapy

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium